In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Celgene takes minority stake in Mesoblast; gets rights of first refusal for certain projects

Executive Summary

Celgene Corp. bought $A58.5mm ($44mm) of Mesoblast Ltd. shares (15.3mm shares at $A3.82, an 11% premium), for a 4.5% stake in the company.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register